Brief: Statera Biopharma Reports Central Institutional Review Board Approval of Trial for Pediatric Crohn's Disease
15/02/2022 14:41
Feb 15 (Reuters) - Statera Biopharma Inc STAB.O :
* STATERA BIOPHARMA, INC., ANNOUNCES CENTRAL INSTITUTIONAL
REVIEW
BOARD APPROVAL OF PHASE 3 CLINICAL TRIAL FOR PEDIATRIC CROHN’S
DISEASE
* STATERA BIOPHARMA INC - PHASE 3 TRIAL EXPECTED TO BEGIN IN
Q2
2022
Source text for Eikon: ID:nGNX1kBsPB
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc